接受辅助生殖女性的血清ω-3脂肪酸与治疗结局
该研究从EARTH前瞻性队列中随机抽取100名女性、136个辅助生殖周期,检测刺激周期第3至9天血清脂肪酸。多变量调整后,血清长链ω3-PUFA每升高1%,临床妊娠和活产概率分别增加8%(4%,11%)和8%(95%CI:1%,16%)。
要点
- 血清长链ω3-PUFA水平较高与辅助生殖后临床妊娠和活产概率较高相关。
- 血清长链ω3-PUFA每升高1%,临床妊娠概率增加8%(4%,11%),活产概率增加8%(95%CI:1%,16%)。
- 用1%能量的长链ω3-PUFA替代1%能量的饱和脂肪酸,活产概率的RR为2.37(95%CI:1.02,5.51)。
核心结论
- 接受辅助生殖的女性中,血清长链ω3-PUFA水平较高与活产概率较高呈正相关。
- 作者认为,增加这类脂肪摄入可能对接受辅助生殖治疗的不孕女性有益。
研究设计与样本
- 分析纳入EARTH前瞻性队列中马萨诸塞总医院生育中心的100名女性随机样本,共136个辅助生殖周期,均在采血后一年内进行。
- 血清脂肪酸以占总脂肪酸百分比表示,采用气相色谱法测定,样本取自刺激周期第3至9天。
- 主要结局为每启动周期的着床、临床妊娠和活产概率,采用聚类加权广义估计方程(GEE)模型分析,并调整年龄、体重指数、吸烟状态、体力活动、复合维生素使用和活产史。
主要发现
- 血清ω3-PUFA中位数[第25,第75百分位]为总脂肪酸的4.7%[3.8%,5.8%]。
- 多变量调整后,血清长链ω3-PUFA每升高1%,临床妊娠概率增加8%(4%,11%),活产概率增加8%(95%CI:1%,16%)。
- 用1%能量的长链ω3-PUFA替代1%能量的饱和脂肪酸,活产概率的RR为2.37(95%CI:1.02,5.51)。
- 血清ω6-PUFA、ω6与ω3-PUFA比值及总PUFA与辅助生殖结局无关。
关键数值与推荐
- 血清长链ω3-PUFA每升高1%,临床妊娠概率增加8%(4%,11%),活产概率增加8%(95%CI:1%,16%)。
- 用1%能量的长链ω3-PUFA替代1%能量的饱和脂肪酸,活产概率的RR为2.37(95%CI:1.02,5.51)。
临床怎么用
- 作者认为,血清长链ω3-PUFA水平较高与辅助生殖结局改善相关,增加这类脂肪摄入可能对接受辅助生殖的不孕女性有益。
局限性
- 研究结果向未接受不孕治疗人群的推广可能有限。
- 使用单次血清脂肪酸测量来反映暴露,可能导致随访期间潜在的错误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are serum polyunsaturated fatty acids (PUFA) concentrations, including omega-3 (ω3-PUFA) and omega-6 (ω6-PUFA), related to ART outcomes? SUMMARY ANSWER: Serum levels of long-chain ω3-PUFA were positively associated with probability of live birth among women undergoing ART. WHAT IS KNOWN ALREADY: Intake of ω3-PUFA improves oocyte and embryo quality in animal and human studies. However, a recent cohort study found no relation between circulating ω3-PUFA levels and pregnancy rates after ART. STUDY DESIGN SIZE, AND DURATION: This analysis included a random sample of 100 women from a prospective cohort study (EARTH) at the Massachusetts General Hospital Fertility Center who underwent 136 ART cycles within one year of blood collection. PARTICIPANTS/MATERIALS, SETTING, METHODS: Serum fatty acids (expressed as percentage of total fatty acids) were measured by gas chromatography in samples taken between Days 3 and 9 of a stimulated cycle. Primary outcomes included the probability of implantation, clinical pregnancy and live birth per initiated cycle. Cluster-weighted generalized estimating equation (GEE) models were used to analyze the association of total and specific PUFAs with ART outcomes adjusting for age, body mass index, smoking status, physical activity, use of multivitamins and history of live birth. MAIN RESULTS AND ROLE OF CHANCE: The median [25th, 75th percentile] serum level of ω3-PUFA was 4.7% [3.8%, 5.8%] of total fatty acids. Higher levels of serum long-chain ω3-PUFA were associated with higher probability of clinical pregnancy and live birth. Specifically, after multivariable adjustment, the probability of clinical pregnancy and live birth increased by 8% (4%, 11%) and 8% (95% CI: 1%, 16%), respectively, for every 1% increase in serum long-chain ω3-PUFA levels. Intake of long-chain ω3-PUFA was also associated with a higher probability of life birth in these women, with RR of 2.37 (95% CI: 1.02, 5.51) when replacing 1% energy of long-chain ω3-PUFA for 1% energy of saturated fatty acids. Serum ω6-PUFA, ratios of ω6 and ω3-PUFA, and total PUFA were not associated with ART outcomes. LIMITATIONS REASONS FOR CAUTION: The generalizability of the findings to populations not undergoing infertility treatment may be limited. The use of a single measurement of serum fatty acids to characterize exposure may lead to potential misclassification during follow up. WIDER IMPLICATIONS OF THE FINDINGS: Serum ω3-PUFA are considered biomarkers of dietary intake. The association of higher serum long chain ω3-PUFA levels with improved ART outcomes suggests that increased intake of these fats be may be beneficial for women undergoing infertility treatment with ART. STUDY FUNDING/COMPETING INTERESTS: NIH grants R01-ES009718 from the National Institute of Environmental Health Sciences, P30-DK046200 and T32-DK007703-16 from the National Institute of Diabetes and Digestive and Kidney Diseases, and L50-HD085359 from the National Institute of Child Health and Human Development, and the Early Life Nutrition Fund from Danone Nutricia US. Dr Rueda is involved in a patent 9,295,662, methods for enhancing, improving, or increasing fertility or reproductive function (http://patents.com/us-9295662.html). This patent, however, does not lead to financial gain for Dr Rueda, or for Massachusetts General Hospital. Dr Rueda does not own any part of the company nor does he have any equity in any fertility related company. As Dr Rueda is not a physician, he does not evaluate patients or prescribe medications. All other coauthors have no conflicts of interest to declare.
引用
- Chiu YH, Karmon AE, Gaskins AJ, et al. Serum omega-3 fatty acids and treatment outcomes among women undergoing assisted reproduction. Hum Reprod. 2018. PMID: 29136189. doi:10.1093/humrep/dex335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。